Initiatives at Churchgate Station and Mahindra & Mahindra focus on early detection, public education, and tobacco-related cancer prevention
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
Vijay brings more than 28 years of experience across healthcare, technology, edtech, manufacturing, and global business environments
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The Hyderabad Public School Society celebrates Dr Rao’s journey from HPS Ramanthapur to becoming one of India's leading medical professionals
Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
Subscribe To Our Newsletter & Stay Updated
